<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="description" content="A comprehensive evidence-based guide to hormone replacement therapy (HRT) for perimenopausal, menopausal, and postmenopausal women, covering risks, benefits, timing, and personalized treatment decisions based on the latest scientific research.">
  <meta name="author" content="AI-Assisted Research">
  <meta property="og:title" content="Hormone Replacement Therapy: A Complete Evidence-Based Guide">
  <meta property="og:description" content="Everything women need to know about HRT risks and benefits, backed by scientific sources.">
  <meta property="og:type" content="article">
  <title>Hormone Replacement Therapy: A Complete Evidence-Based Guide for Menopausal Women</title>

  <style>
    /* CSS Custom Properties */
    :root {
      --color-primary: #7c3aed;
      --color-primary-light: #a78bfa;
      --color-success: #22c55e;
      --color-warning: #f59e0b;
      --color-danger: #ef4444;
      --color-text: #1e293b;
      --color-text-light: #64748b;
      --color-text-lighter: #94a3b8;
      --color-bg: #ffffff;
      --color-bg-alt: #f8fafc;
      --color-bg-section: #f1f5f9;
      --color-border: #e2e8f0;
      --font-sans: 'Inter', system-ui, -apple-system, sans-serif;
      --font-serif: Georgia, 'Times New Roman', serif;
      --font-mono: 'SF Mono', Consolas, monospace;
      --max-width: 820px;
      --nav-width: 280px;
      --shadow-sm: 0 1px 2px rgba(0,0,0,0.05);
      --shadow-md: 0 4px 6px -1px rgba(0,0,0,0.1);
      --shadow-lg: 0 10px 15px -3px rgba(0,0,0,0.1);
      --radius-sm: 6px;
      --radius-md: 10px;
      --radius-lg: 16px;
    }

    [data-theme="dark"] {
      --color-text: #f1f5f9;
      --color-text-light: #94a3b8;
      --color-text-lighter: #64748b;
      --color-bg: #0f172a;
      --color-bg-alt: #1e293b;
      --color-bg-section: #1e293b;
      --color-border: #334155;
    }

    /* Reset & Base */
    *, *::before, *::after { box-sizing: border-box; }

    html {
      scroll-behavior: smooth;
    }

    body {
      font-family: var(--font-sans);
      color: var(--color-text);
      background: var(--color-bg);
      line-height: 1.75;
      margin: 0;
      padding: 0;
      font-size: 17px;
    }

    /* Reading Progress */
    .reading-progress {
      position: fixed;
      top: 0;
      left: 0;
      width: 0%;
      height: 4px;
      background: linear-gradient(90deg, var(--color-primary), var(--color-primary-light));
      z-index: 1000;
      transition: width 0.15s ease-out;
    }

    /* Header */
    .site-header {
      background: linear-gradient(135deg, #7c3aed 0%, #a855f7 50%, #ec4899 100%);
      color: white;
      padding: 3rem 2rem;
      text-align: center;
    }

    .site-header h1 {
      font-size: clamp(1.75rem, 4vw, 2.5rem);
      margin: 0 0 1rem 0;
      font-weight: 800;
      line-height: 1.2;
    }

    .site-header .subtitle {
      font-size: 1.1rem;
      opacity: 0.9;
      max-width: 600px;
      margin: 0 auto 1.5rem;
    }

    .meta-info {
      display: flex;
      justify-content: center;
      gap: 1.5rem;
      flex-wrap: wrap;
      font-size: 0.9rem;
      opacity: 0.85;
    }

    .meta-info span {
      display: flex;
      align-items: center;
      gap: 0.4rem;
    }

    /* Layout */
    .page-wrapper {
      display: flex;
      max-width: 1300px;
      margin: 0 auto;
      position: relative;
    }

    /* Sidebar Navigation */
    .sidebar {
      width: var(--nav-width);
      position: sticky;
      top: 1.5rem;
      height: fit-content;
      padding: 1.5rem;
      display: none;
      flex-shrink: 0;
    }

    @media (min-width: 1100px) {
      .sidebar { display: block; }
    }

    .sidebar h2 {
      font-size: 0.85rem;
      text-transform: uppercase;
      letter-spacing: 0.1em;
      color: var(--color-text-light);
      margin: 0 0 1rem 0;
      padding-bottom: 0.5rem;
      border-bottom: 1px solid var(--color-border);
    }

    .toc-list {
      list-style: none;
      padding: 0;
      margin: 0;
    }

    .toc-item {
      margin: 0.35rem 0;
    }

    .toc-item.sub {
      margin-left: 1rem;
    }

    .toc-link {
      color: var(--color-text-light);
      text-decoration: none;
      font-size: 0.85rem;
      display: block;
      padding: 0.35rem 0.75rem;
      border-radius: var(--radius-sm);
      transition: all 0.2s ease;
      border-left: 2px solid transparent;
    }

    .toc-link:hover {
      color: var(--color-primary);
      background: var(--color-bg-alt);
    }

    .toc-link.active {
      color: var(--color-primary);
      background: rgba(124, 58, 237, 0.1);
      border-left-color: var(--color-primary);
      font-weight: 500;
    }

    /* Main Content */
    .main-content {
      flex: 1;
      max-width: var(--max-width);
      padding: 2.5rem 2rem;
      margin: 0 auto;
      min-width: 0;
    }

    /* Typography */
    h2 {
      font-size: 1.75rem;
      margin: 3.5rem 0 1.5rem;
      padding-bottom: 0.75rem;
      border-bottom: 2px solid var(--color-border);
      color: var(--color-text);
      font-weight: 700;
    }

    h3 {
      font-size: 1.35rem;
      margin: 2.5rem 0 1rem;
      color: var(--color-text);
      font-weight: 600;
    }

    h4 {
      font-size: 1.1rem;
      margin: 2rem 0 0.75rem;
      color: var(--color-text);
      font-weight: 600;
    }

    p {
      margin: 1.25rem 0;
    }

    .lead {
      font-size: 1.15rem;
      color: var(--color-text-light);
      line-height: 1.8;
    }

    strong {
      color: var(--color-text);
      font-weight: 600;
    }

    a {
      color: var(--color-primary);
      text-decoration: none;
    }

    a:hover {
      text-decoration: underline;
    }

    /* Blockquotes */
    blockquote {
      border-left: 4px solid var(--color-primary);
      margin: 2rem 0;
      padding: 1rem 1.5rem;
      background: var(--color-bg-alt);
      border-radius: 0 var(--radius-md) var(--radius-md) 0;
      font-style: italic;
      color: var(--color-text-light);
    }

    /* Lists */
    ul, ol {
      margin: 1.25rem 0;
      padding-left: 1.5rem;
    }

    li {
      margin: 0.5rem 0;
    }

    /* Key Takeaways Box */
    .key-takeaways {
      background: linear-gradient(135deg, rgba(124, 58, 237, 0.08) 0%, rgba(168, 85, 247, 0.08) 100%);
      border: 1px solid rgba(124, 58, 237, 0.2);
      border-radius: var(--radius-lg);
      padding: 1.5rem 2rem;
      margin: 2.5rem 0;
    }

    .key-takeaways h2 {
      margin-top: 0;
      border-bottom: none;
      padding-bottom: 0;
      font-size: 1.25rem;
      color: var(--color-primary);
    }

    .key-takeaways ul {
      margin-bottom: 0;
    }

    .key-takeaways li {
      margin: 0.75rem 0;
    }

    /* Callout boxes */
    .callout {
      padding: 1.25rem 1.5rem;
      border-radius: var(--radius-md);
      margin: 1.5rem 0;
    }

    .callout.info {
      background: rgba(59, 130, 246, 0.1);
      border-left: 4px solid #3b82f6;
    }

    .callout.warning {
      background: rgba(245, 158, 11, 0.1);
      border-left: 4px solid #f59e0b;
    }

    .callout.danger {
      background: rgba(239, 68, 68, 0.1);
      border-left: 4px solid #ef4444;
    }

    .callout.success {
      background: rgba(34, 197, 94, 0.1);
      border-left: 4px solid #22c55e;
    }

    /* Visualization Container */
    .viz-container {
      margin: 2.5rem 0;
      background: var(--color-bg-alt);
      border-radius: var(--radius-lg);
      padding: 1.5rem;
      box-shadow: var(--shadow-sm);
      border: 1px solid var(--color-border);
    }

    .viz-container figure {
      margin: 0;
    }

    .viz-container figcaption {
      margin-top: 1rem;
      padding-top: 1rem;
      border-top: 1px solid var(--color-border);
      font-size: 0.9rem;
      color: var(--color-text-light);
      text-align: center;
    }

    /* Footnotes */
    .footnote-ref {
      color: var(--color-primary);
      text-decoration: none;
      font-size: 0.85em;
      vertical-align: super;
    }

    .footnotes {
      margin-top: 4rem;
      padding-top: 2rem;
      border-top: 2px solid var(--color-border);
    }

    .footnotes h2 {
      font-size: 1.5rem;
      margin-top: 0;
    }

    .footnotes ol {
      font-size: 0.9rem;
      color: var(--color-text-light);
    }

    .footnotes li {
      margin: 1rem 0;
      line-height: 1.6;
    }

    .footnotes a {
      word-break: break-word;
    }

    /* Back to Top Button */
    .back-to-top {
      position: fixed;
      bottom: 2rem;
      right: 2rem;
      background: var(--color-primary);
      color: white;
      border: none;
      border-radius: 50%;
      width: 52px;
      height: 52px;
      cursor: pointer;
      opacity: 0;
      visibility: hidden;
      transform: translateY(20px);
      transition: all 0.3s ease;
      font-size: 1.25rem;
      box-shadow: var(--shadow-lg);
      z-index: 100;
    }

    .back-to-top.visible {
      opacity: 1;
      visibility: visible;
      transform: translateY(0);
    }

    .back-to-top:hover {
      background: var(--color-primary-light);
      transform: translateY(-2px);
    }

    /* Theme Toggle */
    .theme-toggle {
      position: fixed;
      top: 1rem;
      right: 1rem;
      background: var(--color-bg-alt);
      border: 1px solid var(--color-border);
      border-radius: var(--radius-md);
      padding: 0.6rem 1rem;
      cursor: pointer;
      font-size: 1rem;
      z-index: 100;
      box-shadow: var(--shadow-md);
      transition: all 0.2s ease;
    }

    .theme-toggle:hover {
      box-shadow: var(--shadow-lg);
    }

    /* Mobile Navigation */
    .mobile-toc-toggle {
      display: none;
      position: fixed;
      bottom: 2rem;
      left: 2rem;
      background: var(--color-primary);
      color: white;
      border: none;
      border-radius: var(--radius-md);
      padding: 0.75rem 1.25rem;
      cursor: pointer;
      font-size: 0.9rem;
      box-shadow: var(--shadow-lg);
      z-index: 100;
    }

    @media (max-width: 1099px) {
      .mobile-toc-toggle { display: block; }
    }

    .mobile-toc {
      display: none;
      position: fixed;
      bottom: 0;
      left: 0;
      right: 0;
      background: var(--color-bg);
      border-top: 1px solid var(--color-border);
      max-height: 60vh;
      overflow-y: auto;
      padding: 1.5rem;
      z-index: 200;
      box-shadow: 0 -10px 30px rgba(0,0,0,0.15);
    }

    .mobile-toc.active {
      display: block;
    }

    .mobile-toc-close {
      position: absolute;
      top: 1rem;
      right: 1rem;
      background: none;
      border: none;
      font-size: 1.5rem;
      cursor: pointer;
      color: var(--color-text-light);
    }

    /* Responsive */
    @media (max-width: 768px) {
      .main-content {
        padding: 1.5rem 1rem;
      }

      h2 { font-size: 1.5rem; }
      h3 { font-size: 1.2rem; }

      .viz-container {
        padding: 1rem;
        margin: 1.5rem -1rem;
        border-radius: 0;
      }
    }

    /* Print Styles */
    @media print {
      .sidebar, .back-to-top, .theme-toggle, .reading-progress, .mobile-toc-toggle { display: none !important; }
      .main-content { max-width: 100%; padding: 0; }
      .site-header { background: none; color: black; }
      .viz-container { break-inside: avoid; }
    }

    /* Animations */
    @keyframes fadeIn {
      from { opacity: 0; transform: translateY(10px); }
      to { opacity: 1; transform: translateY(0); }
    }

    .main-content section {
      animation: fadeIn 0.5s ease-out;
    }

    /* Chart specific styles */
    .chart-wrapper {
      position: relative;
      width: 100%;
      max-width: 850px;
      margin: 0 auto;
    }

    /* Custom scrollbar */
    ::-webkit-scrollbar {
      width: 8px;
    }

    ::-webkit-scrollbar-track {
      background: var(--color-bg-alt);
    }

    ::-webkit-scrollbar-thumb {
      background: var(--color-text-lighter);
      border-radius: 4px;
    }

    ::-webkit-scrollbar-thumb:hover {
      background: var(--color-text-light);
    }
  </style>
</head>
<body>
  <div class="reading-progress" id="progress"></div>

  <button class="theme-toggle" onclick="toggleTheme()" aria-label="Toggle dark mode">
    <span id="theme-icon">&#x1F319;</span>
  </button>

  <header class="site-header">
    <h1>Hormone Replacement Therapy: A Complete Evidence-Based Guide</h1>
    <p class="subtitle">Understanding the risks, benefits, and science behind HRT for perimenopausal, menopausal, and postmenopausal women</p>
    <div class="meta-info">
      <span>&#x1F4C5; December 2025</span>
      <span>&#x23F1; 18 min read</span>
      <span>&#x1F4DA; 33 scientific sources</span>
    </div>
  </header>

  <div class="page-wrapper">
    <nav class="sidebar" aria-label="Table of Contents">
      <h2>Contents</h2>
      <ul class="toc-list">
        <li class="toc-item"><a class="toc-link" href="#understanding">Understanding Menopause & HRT</a></li>
        <li class="toc-item"><a class="toc-link" href="#whi">The WHI Study: What We Know Now</a></li>
        <li class="toc-item"><a class="toc-link" href="#timing">The Timing Hypothesis</a></li>
        <li class="toc-item"><a class="toc-link" href="#benefits">Benefits of Hormone Therapy</a></li>
        <li class="toc-item"><a class="toc-link" href="#risks">Risks of Hormone Therapy</a></li>
        <li class="toc-item"><a class="toc-link" href="#routes">Route of Administration</a></li>
        <li class="toc-item"><a class="toc-link" href="#duration">Duration of Therapy</a></li>
        <li class="toc-item"><a class="toc-link" href="#risk-factors">Individual Risk Factors</a></li>
        <li class="toc-item"><a class="toc-link" href="#decision">Making the Decision</a></li>
        <li class="toc-item"><a class="toc-link" href="#takeaways">Key Takeaways</a></li>
        <li class="toc-item"><a class="toc-link" href="#sources">Sources</a></li>
      </ul>
    </nav>

    <main class="main-content">
      <article>
        <section id="intro">
          <p class="lead">Two decades after the Women's Health Initiative (WHI) study sent shockwaves through the medical community and caused millions of women to abandon hormone therapy, the scientific consensus has dramatically shifted. In November 2025, the FDA removed the black box warnings from many hormone replacement products, acknowledging that the original findings presented a misleadingly alarming picture.<sup><a href="#fn1" class="footnote-ref">1</a></sup></p>

          <p>What we now understand is far more nuanced: <strong>the risks and benefits of hormone replacement therapy (HRT) depend critically on when it's started, how it's delivered, and who's taking it.</strong></p>

          <p>For the estimated 1.3 million women who enter menopause each year in the United States alone, this evolving understanding represents a crucial opportunity. Menopausal symptoms&mdash;including hot flashes that can persist for 7 to 11 years on average<sup><a href="#fn2" class="footnote-ref">2</a></sup>&mdash;significantly impact quality of life, productivity, and long-term health. HRT remains the most effective treatment for these symptoms, yet fear and confusion continue to prevent many women from accessing relief.</p>
        </section>

        <section id="understanding">
          <h2>Understanding Menopause and Hormone Therapy</h2>

          <h3>The Menopausal Transition</h3>
          <p>Menopause marks the permanent cessation of menstruation, typically occurring around age 51. However, the transition begins earlier during perimenopause, when hormone levels begin fluctuating. This transition brings a constellation of symptoms: vasomotor symptoms (hot flashes and night sweats), sleep disturbances, mood changes, vaginal dryness, and accelerated bone loss.</p>

          <p>Approximately <strong>27% to 84% of postmenopausal women</strong> experience genitourinary syndrome of menopause (GSM), which can significantly impair sexual function and quality of life.<sup><a href="#fn3" class="footnote-ref">3</a></sup></p>

          <h3>Types of Hormone Therapy</h3>

          <p><strong>Estrogen-Only Therapy (ET)</strong> is prescribed for women who have had a hysterectomy. Without a uterus, there's no risk of endometrial cancer from unopposed estrogen, making progestogen unnecessary. Importantly, the WHI found that estrogen-only therapy <strong>reduces breast cancer risk by 23% and breast cancer mortality by 40%</strong>&mdash;a stark contrast to the increased risk seen with combined therapy.<sup><a href="#fn4" class="footnote-ref">4</a></sup></p>

          <p><strong>Combined Estrogen-Progestogen Therapy (EPT)</strong> is necessary for women with an intact uterus. Estrogen alone increases endometrial cancer risk; adding a progestogen provides crucial protection. However, this combination carries different risks, including a modest increase in breast cancer risk.</p>

          <p><strong>Bioidentical vs. Synthetic Hormones</strong> remains an area of ongoing debate. Bioidentical hormones (17&beta;-estradiol, progesterone) are chemically identical to those produced by the body. Some evidence suggests natural progesterone may carry lower breast cancer risk than synthetic progestins like medroxyprogesterone acetate (MPA).<sup><a href="#fn5" class="footnote-ref">5</a></sup> However, the FDA and Endocrine Society emphasize that compounded bioidentical hormones lack rigorous testing and quality control.<sup><a href="#fn6" class="footnote-ref">6</a></sup></p>
        </section>

        <section id="whi">
          <h2>The Women's Health Initiative: What We Know Now</h2>

          <h3>The Original Findings</h3>
          <p>The WHI enrolled 27,347 postmenopausal women between 1993 and 1998 in two parallel hormone therapy trials. The estrogen-plus-progestin arm was halted in 2002 after findings suggested increased risks of coronary heart disease, stroke, blood clots, and breast cancer. Headlines around the world declared hormone therapy dangerous, and prescriptions plummeted by 80% in subsequent years.<sup><a href="#fn7" class="footnote-ref">7</a></sup></p>

          <!-- Visualization 1: WHI Outcomes -->
          <div class="viz-container">
            <figure>
              <div class="chart-wrapper" style="height: 400px;">
                <canvas id="chart-whi"></canvas>
              </div>
              <figcaption>
                <strong>Figure 1:</strong> Comparison of health outcomes between estrogen-only therapy (ET) and combined estrogen-progestogen therapy (EPT) from the WHI trials. Values below 1.0 indicate reduced risk (benefit), above 1.0 indicate increased risk (harm).<br>
                <small style="color: var(--color-text-lighter);">Source: The Women's Health Initiative Hormone Therapy Trials (PMC3963523)</small>
              </figcaption>
            </figure>
          </div>

          <h3>The Critical Context Missing from Headlines</h3>
          <p>What was often lost in the panic was crucial context. <strong>The average age of WHI participants was 63</strong>&mdash;more than a decade past the typical age of menopause. Only 3.5% were aged 50-54, the window when most women consider starting hormone therapy.<sup><a href="#fn7" class="footnote-ref">7</a></sup></p>

          <p>Furthermore, many initial findings were not statistically significant when properly adjusted. A critical review noted that after adjustment for multiple comparisons, the breast cancer hazard ratio's confidence interval widened to 0.83-1.92, crossing the null value and indicating no significant effect.<sup><a href="#fn8" class="footnote-ref">8</a></sup></p>

          <p>Even accepting the WHI estimates at face value, the absolute risk was modest: combined therapy was associated with approximately <strong>one additional nonfatal breast cancer case per 1,000 women treated annually</strong>.<sup><a href="#fn8" class="footnote-ref">8</a></sup></p>
        </section>

        <section id="timing">
          <h2>The Timing Hypothesis: When You Start Matters Profoundly</h2>

          <p>Perhaps the most important insight from post-WHI research is the "timing hypothesis"&mdash;the understanding that HRT's effects depend critically on when therapy begins relative to menopause onset.</p>

          <!-- Visualization 2: Timing Hypothesis -->
          <div class="viz-container">
            <figure>
              <div class="chart-wrapper" style="height: 350px;">
                <canvas id="chart-timing"></canvas>
              </div>
              <figcaption>
                <strong>Figure 2:</strong> The "timing hypothesis" illustrated: Coronary heart disease risk varies dramatically based on when hormone therapy is initiated. Women starting within 10 years of menopause experience a 24% reduction in CHD risk.<br>
                <small style="color: var(--color-text-lighter);">Source: Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and CVD (PMC9178928)</small>
              </figcaption>
            </figure>
          </div>

          <p>The ELITE trial, specifically designed to test this hypothesis, confirmed that estradiol treatment slowed progression of carotid artery thickening when initiated within 6 years of menopause, but provided no benefit when started 10 or more years after menopause.<sup><a href="#fn10" class="footnote-ref">10</a></sup></p>

          <h3>Age-Stratified Outcomes</h3>

          <!-- Visualization 3: Age Outcomes -->
          <div class="viz-container">
            <figure>
              <div class="chart-wrapper" style="height: 320px;">
                <canvas id="chart-age"></canvas>
              </div>
              <figcaption>
                <strong>Figure 3:</strong> Age-stratified outcomes from the WHI estrogen-only arm demonstrate that HRT effects depend critically on age. Younger women experience net benefits, while older women experience net harms.<br>
                <small style="color: var(--color-text-lighter);">Source: The Women's Health Initiative Hormone Therapy Trials (PMC3963523)</small>
              </figcaption>
            </figure>
          </div>

          <p>Among women aged 50-59 taking estrogen alone, there were <strong>19 fewer adverse events per 10,000 person-years</strong> compared to placebo. For women aged 70-79, there were <strong>51 more adverse events</strong>. This reversal underscores why applying findings from older women to younger ones was scientifically inappropriate.</p>
        </section>

        <section id="benefits">
          <h2>Benefits of Hormone Therapy</h2>

          <!-- Visualization 4: Benefits -->
          <div class="viz-container">
            <figure>
              <div class="chart-wrapper" style="height: 380px;">
                <canvas id="chart-benefits"></canvas>
              </div>
              <figcaption>
                <strong>Figure 4:</strong> Evidence-based benefits of hormone replacement therapy when initiated appropriately (within 10 years of menopause or before age 60).<br>
                <small style="color: var(--color-text-lighter);">Sources: WHI Trials, Cardiovascular Meta-analysis, Cognition Meta-analysis</small>
              </figcaption>
            </figure>
          </div>

          <h3>Vasomotor Symptom Relief</h3>
          <p>HRT remains unequivocally the most effective treatment for hot flashes and night sweats. In the WHI, women aged 50-54 with moderate to severe symptoms experienced a <strong>64% reduction in vasomotor symptoms</strong> at one year.<sup><a href="#fn7" class="footnote-ref">7</a></sup> No other therapy approaches this level of efficacy.</p>

          <h3>Bone Health and Fracture Prevention</h3>
          <p>The WHI demonstrated a <strong>34% reduction in hip fracture</strong> and <strong>24% reduction in all fractures</strong>, benefits that persisted regardless of baseline bone mineral density.<sup><a href="#fn15" class="footnote-ref">15</a></sup></p>

          <h3>Cognitive Effects</h3>
          <p>Mid-life estrogen therapy is associated with a <strong>32% lower rate of dementia</strong>, while late-life initiation shows no benefit and may even cause harm.<sup><a href="#fn16" class="footnote-ref">16</a></sup></p>

          <h3>Cardiovascular Protection (Early Initiation)</h3>
          <p>When initiated within 10 years of menopause or before age 60, HRT is associated with reduced coronary heart disease risk (HR 0.76) and may reduce cardiovascular disease by up to 50%.<sup><a href="#fn9" class="footnote-ref">9</a></sup></p>
        </section>

        <section id="risks">
          <h2>Risks of Hormone Therapy</h2>

          <h3>Breast Cancer</h3>

          <!-- Visualization 5: Breast Cancer -->
          <div class="viz-container">
            <figure>
              <div class="chart-wrapper" style="height: 350px;">
                <canvas id="chart-breast"></canvas>
              </div>
              <figcaption>
                <strong>Figure 5:</strong> Breast cancer risk varies dramatically by type of hormone therapy. Estrogen-only therapy actually <em>reduces</em> risk, while combined therapy with synthetic progestins increases it.<br>
                <small style="color: var(--color-text-lighter);">Sources: WHI Trials (PMC3963523), Progestins and Breast Cancer Risk (PMC1974841)</small>
              </figcaption>
            </figure>
          </div>

          <div class="callout info">
            <strong>Key Insight:</strong> The type of HRT matters. Estrogen-only therapy (for hysterectomized women) reduces breast cancer risk by 23%, while combined therapy with synthetic progestins like MPA increases it by 24%.
          </div>

          <h3>Venous Thromboembolism</h3>
          <p>Blood clot risk is genuinely elevated with oral HRT, with meta-analyses showing a relative risk of 1.86&mdash;nearly double the baseline risk.<sup><a href="#fn21" class="footnote-ref">21</a></sup> However, route of administration is critically important:</p>

          <!-- Visualization 6: VTE Route -->
          <div class="viz-container">
            <figure>
              <div class="chart-wrapper" style="height: 300px;">
                <canvas id="chart-vte"></canvas>
              </div>
              <figcaption>
                <strong>Figure 6:</strong> Route of administration dramatically affects blood clot risk. Transdermal delivery shows no increased VTE risk.<br>
                <small style="color: var(--color-text-lighter);">Source: Hormonal therapies and venous thrombosis (PMC9399360)</small>
              </figcaption>
            </figure>
          </div>

          <h3>Stroke</h3>
          <p>Meta-analyses consistently show HRT increases stroke risk by approximately 23-32%.<sup><a href="#fn21" class="footnote-ref">21</a></sup> This risk appears limited to ischemic stroke and is present during but not after HRT use. <strong>Transdermal administration does not appear to increase stroke risk.</strong><sup><a href="#fn24" class="footnote-ref">24</a></sup></p>
        </section>

        <section id="routes">
          <h2>Route of Administration: Transdermal vs. Oral</h2>

          <h3>Transdermal Advantages</h3>
          <p>Patches, gels, and sprays bypass first-pass liver metabolism, leading to:<sup><a href="#fn26" class="footnote-ref">26</a></sup></p>
          <ul>
            <li><strong>No increased VTE risk</strong> (RR 1.0 vs. 1.9 for oral)</li>
            <li><strong>Lower stroke risk</strong></li>
            <li><strong>Lower doses required</strong> (10-20 times lower than oral)</li>
            <li><strong>Reduced gallbladder disease risk</strong></li>
            <li><strong>Lower anxiety and depression incidence</strong></li>
          </ul>

          <h3>Who Should Use Transdermal</h3>
          <p>Transdermal delivery is particularly recommended for:</p>
          <ul>
            <li>Women with VTE risk factors (prior clots, Factor V Leiden, family history)</li>
            <li>Obese women</li>
            <li>Women over 60</li>
            <li>Smokers</li>
            <li>Those with migraine with aura</li>
          </ul>
        </section>

        <section id="duration">
          <h2>Duration of Therapy: How Long Is Safe?</h2>

          <p>Medical guidelines have evolved significantly on duration:</p>
          <ul>
            <li><strong>ACOG and The Menopause Society:</strong> No maximum duration for MHT use<sup><a href="#fn2" class="footnote-ref">2</a></sup></li>
            <li><strong>NHS:</strong> No definitive limit on HRT duration<sup><a href="#fn28" class="footnote-ref">28</a></sup></li>
            <li><strong>Previous 5-year limits:</strong> Not based on quality evidence<sup><a href="#fn29" class="footnote-ref">29</a></sup></li>
          </ul>

          <p>The key principle is <strong>individualization</strong>. Symptoms often last longer than previously thought (average 7-11 years for vasomotor symptoms). Annual review with a healthcare provider is recommended.</p>

          <p>The Menopause Society confirms that <strong>women up to age 80 can benefit from individualized therapy</strong>.<sup><a href="#fn31" class="footnote-ref">31</a></sup></p>
        </section>

        <section id="risk-factors">
          <h2>Individual Risk Factors: Who Benefits Most?</h2>

          <h3>Ideal Candidates</h3>
          <ul>
            <li>Women under 60 or within 10 years of menopause</li>
            <li>Those with moderate to severe vasomotor symptoms</li>
            <li>Women at elevated osteoporosis risk</li>
            <li>Women with premature or early menopause</li>
            <li>Surgically menopausal women (oophorectomy)</li>
          </ul>

          <h3>Contraindications (Avoid HRT)</h3>
          <div class="callout danger">
            <strong>HRT is contraindicated in women with:</strong>
            <ul style="margin-bottom: 0;">
              <li>History of breast cancer</li>
              <li>Active venous thromboembolism or pulmonary embolism</li>
              <li>History of stroke or myocardial infarction</li>
              <li>Active liver disease</li>
              <li>Undiagnosed vaginal bleeding</li>
            </ul>
          </div>

          <h3>Risk Mitigation Strategies</h3>
          <p>For women who need HRT but have elevated risk:</p>
          <ul>
            <li>Use <strong>transdermal</strong> rather than oral estrogen</li>
            <li>Choose <strong>bioidentical progesterone</strong> over synthetic progestins when possible</li>
            <li>Use <strong>lowest effective dose</strong></li>
            <li>Consider <strong>vaginal estrogen</strong> for localized symptoms only</li>
            <li>Regular monitoring and annual review</li>
          </ul>
        </section>

        <section id="decision">
          <h2>Making the Decision: A Framework</h2>

          <!-- Visualization 7: Decision Framework -->
          <div class="viz-container" style="background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);">
            <h3 style="text-align: center; margin-top: 0; color: var(--color-text);">HRT Decision Framework</h3>

            <div style="max-width: 700px; margin: 0 auto;">
              <div style="display: flex; gap: 1rem; margin-bottom: 1.5rem; flex-wrap: wrap;">
                <div style="flex: 1; min-width: 250px; background: white; padding: 1.25rem; border-radius: 10px; border-left: 4px solid var(--color-primary);">
                  <h4 style="margin: 0 0 0.5rem; color: var(--color-primary);">Step 1: Timing</h4>
                  <p style="margin: 0; font-size: 0.95rem;">Are you under 60 or within 10 years of menopause? This is the optimal window for HRT benefits.</p>
                </div>
                <div style="flex: 1; min-width: 250px; background: white; padding: 1.25rem; border-radius: 10px; border-left: 4px solid var(--color-success);">
                  <h4 style="margin: 0 0 0.5rem; color: var(--color-success);">Step 2: Symptoms</h4>
                  <p style="margin: 0; font-size: 0.95rem;">Do you have moderate to severe symptoms impacting quality of life?</p>
                </div>
              </div>

              <div style="display: flex; gap: 1rem; margin-bottom: 1.5rem; flex-wrap: wrap;">
                <div style="flex: 1; min-width: 250px; background: white; padding: 1.25rem; border-radius: 10px; border-left: 4px solid var(--color-danger);">
                  <h4 style="margin: 0 0 0.5rem; color: var(--color-danger);">Step 3: Contraindications</h4>
                  <p style="margin: 0; font-size: 0.95rem;">Check for breast cancer history, VTE, stroke, MI, or active liver disease.</p>
                </div>
                <div style="flex: 1; min-width: 250px; background: white; padding: 1.25rem; border-radius: 10px; border-left: 4px solid var(--color-warning);">
                  <h4 style="margin: 0 0 0.5rem; color: var(--color-warning);">Step 4: Route Selection</h4>
                  <p style="margin: 0; font-size: 0.95rem;">Transdermal preferred for most; essential for those with VTE risk factors.</p>
                </div>
              </div>

              <div style="background: linear-gradient(135deg, rgba(124, 58, 237, 0.1) 0%, rgba(168, 85, 247, 0.1) 100%); padding: 1.25rem; border-radius: 10px; text-align: center; border: 2px solid var(--color-primary);">
                <strong style="color: var(--color-primary);">Discuss with Your Healthcare Provider</strong>
                <p style="margin: 0.5rem 0 0; font-size: 0.9rem; color: var(--color-text-light);">Individual decisions should be made with a healthcare provider who can assess your complete medical history. Annual review is recommended.</p>
              </div>
            </div>
          </div>
        </section>

        <section id="takeaways" class="key-takeaways">
          <h2>Key Takeaways</h2>
          <ul>
            <li><strong>Timing is crucial:</strong> HRT initiated before age 60 or within 10 years of menopause has a favorable risk-benefit profile; later initiation may pose risks without benefits</li>
            <li><strong>Not all HRT is equal:</strong> Estrogen-only therapy reduces breast cancer risk; combined therapy modestly increases it</li>
            <li><strong>Route matters:</strong> Transdermal delivery avoids the blood clot and stroke risks associated with oral therapy</li>
            <li><strong>Duration is individualized:</strong> No maximum treatment length; decisions should be based on ongoing symptom burden and risk assessment</li>
            <li><strong>The evidence has evolved:</strong> The 2002 WHI findings should not prevent younger symptomatic women from accessing effective treatment</li>
          </ul>
        </section>

        <section>
          <h2>Conclusion</h2>
          <p>The landscape of hormone replacement therapy has transformed since the alarm bells of 2002. We now understand that for the right woman at the right time, HRT offers significant benefits&mdash;relief from debilitating symptoms, protection against bone loss, and potentially reduced cardiovascular and cognitive risks&mdash;with manageable risks. The 2025 removal of FDA black box warnings reflects this evolved understanding.</p>

          <p>For women experiencing menopausal symptoms, the decision about HRT is deeply personal and should be made in partnership with a knowledgeable healthcare provider. The goal is not to convince everyone to take hormones, nor to frighten women away from effective treatment. It is to ensure that <strong>every woman has access to accurate, evidence-based information</strong> to make the choice that's right for her individual circumstances.</p>

          <p>The average duration of vasomotor symptoms&mdash;7 to 11 years&mdash;represents a significant portion of a woman's life. Every woman deserves to navigate this transition with the best available evidence guiding her care.</p>
        </section>

        <section id="sources" class="footnotes">
          <h2>Sources</h2>
          <ol>
            <li id="fn1">HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy (2025). <a href="https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html" target="_blank" rel="noopener">HHS.gov</a></li>
            <li id="fn2">The 2020 Menopausal Hormone Therapy Guidelines. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7475284/" target="_blank" rel="noopener">PMC7475284</a></li>
            <li id="fn3">Genitourinary Syndrome of Menopause: A Narrative Review. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10692865/" target="_blank" rel="noopener">PMC10692865</a></li>
            <li id="fn4">'Tis but a scratch: A critical review of WHI breast cancer evidence. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10758198/" target="_blank" rel="noopener">PMC10758198</a></li>
            <li id="fn5">A comprehensive review of the safety and efficacy of bioidentical hormones. <a href="https://pubmed.ncbi.nlm.nih.gov/17217322/" target="_blank" rel="noopener">PubMed 17217322</a></li>
            <li id="fn6">Compounded Bioidentical Menopausal Hormone Therapy. <a href="https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy" target="_blank" rel="noopener">ACOG</a></li>
            <li id="fn7">The Women's Health Initiative Hormone Therapy Trials: Update and Overview. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3963523/" target="_blank" rel="noopener">PMC3963523</a></li>
            <li id="fn8">'Tis but a scratch: Statistical analysis of WHI findings. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10758198/" target="_blank" rel="noopener">PMC10758198</a></li>
            <li id="fn9">Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and CVD. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928/" target="_blank" rel="noopener">PMC9178928</a></li>
            <li id="fn10">ELITE Trial: Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1505241" target="_blank" rel="noopener">NEJM</a></li>
            <li id="fn11">When Women Initiate Estrogen Therapy Matters. <a href="https://menopause.org/press-releases/when-women-initiate-estrogen-therapy-matters" target="_blank" rel="noopener">The Menopause Society</a></li>
            <li id="fn12">Estrogen and Cardiovascular Disease: Is Timing Everything? <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4490077/" target="_blank" rel="noopener">PMC4490077</a></li>
            <li id="fn13">Vasomotor Symptoms During Menopause: A Practical Guide. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9938702/" target="_blank" rel="noopener">PMC9938702</a></li>
            <li id="fn14">Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10752002/" target="_blank" rel="noopener">PMC10752002</a></li>
            <li id="fn15">Menopausal hormone therapy for the management of osteoporosis. <a href="https://pubmed.ncbi.nlm.nih.gov/34119418/" target="_blank" rel="noopener">PubMed 34119418</a></li>
            <li id="fn16">The Role of Estrogen Therapy as a Protective Factor for Alzheimer's Disease. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10480684/" target="_blank" rel="noopener">PMC10480684</a></li>
            <li id="fn17">Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. <a href="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1350318/full" target="_blank" rel="noopener">Frontiers in Endocrinology</a></li>
            <li id="fn18">Hormone replacement therapy is associated with improved cognition in at-risk APOE4 women. <a href="https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01121-5" target="_blank" rel="noopener">Alzheimer's Research & Therapy</a></li>
            <li id="fn19">Effectiveness and safety of hormone replacement therapy in the treatment of menopausal syndrome: a meta-analysis. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11826161/" target="_blank" rel="noopener">PMC11826161</a></li>
            <li id="fn20">Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1974841/" target="_blank" rel="noopener">PMC1974841</a></li>
            <li id="fn21">The benefits and risks of menopause hormone therapy for the cardiovascular system: systematic review and meta-analysis. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10804786/" target="_blank" rel="noopener">PMC10804786</a></li>
            <li id="fn22">Hormonal therapies and venous thrombosis: Considerations for prevention and management. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9399360/" target="_blank" rel="noopener">PMC9399360</a></li>
            <li id="fn23">Risk of stroke in healthy postmenopausal women during and after hormone therapy. <a href="https://pubmed.ncbi.nlm.nih.gov/24686450/" target="_blank" rel="noopener">PubMed 24686450</a></li>
            <li id="fn24">Risk of Stroke With Various Types of Menopausal Hormone Therapies. <a href="https://www.ahajournals.org/doi/10.1161/strokeaha.117.017132" target="_blank" rel="noopener">Stroke/AHA</a></li>
            <li id="fn25">Hormone Replacement Therapy - StatPearls. <a href="https://www.ncbi.nlm.nih.gov/books/NBK493191/" target="_blank" rel="noopener">NCBI Bookshelf</a></li>
            <li id="fn26">Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10147786/" target="_blank" rel="noopener">PMC10147786</a></li>
            <li id="fn27">Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025). <a href="https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopause" target="_blank" rel="noopener">AUA</a></li>
            <li id="fn28">When to take hormone replacement therapy (HRT). <a href="https://www.nhs.uk/medicines/hormone-replacement-therapy-hrt/when-to-take-hormone-replacement-therapy-hrt/" target="_blank" rel="noopener">NHS</a></li>
            <li id="fn29">Starting or continuing HRT many years after your menopause. <a href="https://themenopausecharity.org/information-and-support/what-can-help/treatment-options/starting-or-continuing-hrt-many-years-after-your-menopause/" target="_blank" rel="noopener">The Menopause Charity</a></li>
            <li id="fn30">How Long Should I Take Hormone Therapy in Menopause? <a href="https://www.evernow.com/learn/how-long-should-i-take-hormone-replacement-therapy" target="_blank" rel="noopener">Evernow</a></li>
            <li id="fn31">Ongoing Individualized Hormone Therapy Appears to Have No Age Limit. <a href="https://menopause.org/press-releases/ongoing-individualized-hormone-therapy-appears-to-have-no-age-limit" target="_blank" rel="noopener">The Menopause Society</a></li>
            <li id="fn32">Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? <a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061559" target="_blank" rel="noopener">Circulation</a></li>
            <li id="fn33">Menopausal Hormone Therapy and Heart Risk: Updated Guidance. <a href="https://consultqd.clevelandclinic.org/menopausal-hormone-therapy-and-heart-risk-updated-guidance-is-at-hand" target="_blank" rel="noopener">Cleveland Clinic</a></li>
          </ol>
        </section>
      </article>
    </main>
  </div>

  <button class="back-to-top" id="backToTop" aria-label="Back to top">&#x2191;</button>

  <button class="mobile-toc-toggle" onclick="toggleMobileToc()">&#x2630; Contents</button>

  <div class="mobile-toc" id="mobileToc">
    <button class="mobile-toc-close" onclick="toggleMobileToc()">&times;</button>
    <h3>Contents</h3>
    <ul class="toc-list">
      <li class="toc-item"><a class="toc-link" href="#understanding" onclick="toggleMobileToc()">Understanding Menopause & HRT</a></li>
      <li class="toc-item"><a class="toc-link" href="#whi" onclick="toggleMobileToc()">The WHI Study</a></li>
      <li class="toc-item"><a class="toc-link" href="#timing" onclick="toggleMobileToc()">The Timing Hypothesis</a></li>
      <li class="toc-item"><a class="toc-link" href="#benefits" onclick="toggleMobileToc()">Benefits</a></li>
      <li class="toc-item"><a class="toc-link" href="#risks" onclick="toggleMobileToc()">Risks</a></li>
      <li class="toc-item"><a class="toc-link" href="#routes" onclick="toggleMobileToc()">Route of Administration</a></li>
      <li class="toc-item"><a class="toc-link" href="#duration" onclick="toggleMobileToc()">Duration</a></li>
      <li class="toc-item"><a class="toc-link" href="#risk-factors" onclick="toggleMobileToc()">Risk Factors</a></li>
      <li class="toc-item"><a class="toc-link" href="#decision" onclick="toggleMobileToc()">Decision Framework</a></li>
      <li class="toc-item"><a class="toc-link" href="#takeaways" onclick="toggleMobileToc()">Key Takeaways</a></li>
      <li class="toc-item"><a class="toc-link" href="#sources" onclick="toggleMobileToc()">Sources</a></li>
    </ul>
  </div>

  <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
  <script src="https://cdn.jsdelivr.net/npm/chartjs-plugin-annotation"></script>
  <script>
    // Theme handling
    function toggleTheme() {
      const isDark = document.documentElement.toggleAttribute('data-theme');
      localStorage.setItem('theme', isDark ? 'dark' : 'light');
      document.getElementById('theme-icon').innerHTML = isDark ? '&#x2600;' : '&#x1F319;';
    }

    // Load saved theme
    if (localStorage.getItem('theme') === 'dark') {
      document.documentElement.setAttribute('data-theme', 'dark');
      document.getElementById('theme-icon').innerHTML = '&#x2600;';
    }

    // Reading progress
    window.addEventListener('scroll', () => {
      const winScroll = document.documentElement.scrollTop;
      const height = document.documentElement.scrollHeight - document.documentElement.clientHeight;
      document.getElementById('progress').style.width = (winScroll / height * 100) + '%';

      // Back to top visibility
      document.getElementById('backToTop').classList.toggle('visible', winScroll > 500);
    });

    // Back to top
    document.getElementById('backToTop').addEventListener('click', () => {
      window.scrollTo({ top: 0, behavior: 'smooth' });
    });

    // Mobile TOC
    function toggleMobileToc() {
      document.getElementById('mobileToc').classList.toggle('active');
    }

    // Scroll spy for TOC
    const observerOptions = {
      root: null,
      rootMargin: '-20% 0px -70% 0px',
      threshold: 0
    };

    const observer = new IntersectionObserver((entries) => {
      entries.forEach(entry => {
        if (entry.isIntersecting) {
          const id = entry.target.getAttribute('id');
          document.querySelectorAll('.toc-link').forEach(link => {
            link.classList.toggle('active', link.getAttribute('href') === '#' + id);
          });
        }
      });
    }, observerOptions);

    document.querySelectorAll('section[id]').forEach(section => observer.observe(section));

    // Chart 1: WHI Outcomes
    new Chart(document.getElementById('chart-whi'), {
      type: 'bar',
      data: {
        labels: ['Breast Cancer', 'CHD', 'Stroke', 'VTE', 'Hip Fracture', 'All-Cause Mortality'],
        datasets: [
          {
            label: 'Estrogen-Only (ET)',
            data: [0.79, 0.94, 1.35, 1.35, 0.67, 0.99],
            backgroundColor: 'rgba(59, 130, 246, 0.8)',
            borderColor: 'rgba(59, 130, 246, 1)',
            borderWidth: 2,
            borderRadius: 4
          },
          {
            label: 'Combined (EPT)',
            data: [1.24, 1.18, 1.37, 2.0, 0.67, 0.99],
            backgroundColor: 'rgba(244, 63, 94, 0.8)',
            borderColor: 'rgba(244, 63, 94, 1)',
            borderWidth: 2,
            borderRadius: 4
          }
        ]
      },
      options: {
        responsive: true,
        maintainAspectRatio: false,
        plugins: {
          title: { display: false },
          legend: { position: 'bottom', labels: { padding: 20, usePointStyle: true } },
          tooltip: {
            callbacks: {
              label: (ctx) => {
                const hr = ctx.raw;
                const pct = hr < 1 ? `${Math.round((1-hr)*100)}% lower` : hr > 1 ? `${Math.round((hr-1)*100)}% higher` : 'No change';
                return `${ctx.dataset.label}: HR ${hr} (${pct})`;
              }
            }
          },
          annotation: {
            annotations: {
              line1: { type: 'line', yMin: 1, yMax: 1, borderColor: 'rgba(100, 116, 139, 0.6)', borderWidth: 2, borderDash: [6, 4] }
            }
          }
        },
        scales: {
          y: { beginAtZero: true, max: 2.2, title: { display: true, text: 'Hazard Ratio' } },
          x: { grid: { display: false } }
        }
      }
    });

    // Chart 2: Timing Hypothesis
    new Chart(document.getElementById('chart-timing'), {
      type: 'bar',
      data: {
        labels: ['< 10 years post-menopause', '10-19 years', '20+ years'],
        datasets: [{
          label: 'CHD Hazard Ratio',
          data: [0.76, 1.10, 1.28],
          backgroundColor: ['rgba(34, 197, 94, 0.85)', 'rgba(251, 191, 36, 0.85)', 'rgba(239, 68, 68, 0.85)'],
          borderColor: ['rgba(34, 197, 94, 1)', 'rgba(251, 191, 36, 1)', 'rgba(239, 68, 68, 1)'],
          borderWidth: 2,
          borderRadius: 8,
          barThickness: 70
        }]
      },
      options: {
        responsive: true,
        maintainAspectRatio: false,
        plugins: {
          legend: { display: false },
          tooltip: {
            callbacks: {
              label: (ctx) => {
                const hr = ctx.raw;
                if (hr < 1) return `HR ${hr}: ${Math.round((1-hr)*100)}% LOWER CHD risk`;
                return `HR ${hr}: ${Math.round((hr-1)*100)}% HIGHER CHD risk`;
              }
            }
          },
          annotation: {
            annotations: {
              line1: { type: 'line', yMin: 1, yMax: 1, borderColor: 'rgba(100, 116, 139, 0.7)', borderWidth: 2, borderDash: [6, 4] }
            }
          }
        },
        scales: {
          y: { beginAtZero: true, max: 1.5, title: { display: true, text: 'Hazard Ratio for CHD' } },
          x: { grid: { display: false } }
        }
      }
    });

    // Chart 3: Age Outcomes
    new Chart(document.getElementById('chart-age'), {
      type: 'bar',
      data: {
        labels: ['Ages 50-59', 'Ages 60-69', 'Ages 70-79'],
        datasets: [{
          label: 'Events per 10,000 person-years',
          data: [-19, 4, 51],
          backgroundColor: (ctx) => ctx.raw < 0 ? 'rgba(34, 197, 94, 0.8)' : ctx.raw < 10 ? 'rgba(148, 163, 184, 0.8)' : 'rgba(239, 68, 68, 0.8)',
          borderColor: (ctx) => ctx.raw < 0 ? 'rgba(34, 197, 94, 1)' : ctx.raw < 10 ? 'rgba(148, 163, 184, 1)' : 'rgba(239, 68, 68, 1)',
          borderWidth: 2,
          borderRadius: 6
        }]
      },
      options: {
        indexAxis: 'y',
        responsive: true,
        maintainAspectRatio: false,
        plugins: {
          legend: { display: false },
          tooltip: {
            callbacks: {
              label: (ctx) => {
                const val = ctx.raw;
                if (val < 0) return `${Math.abs(val)} FEWER adverse events (benefit)`;
                return `${val} MORE adverse events (harm)`;
              }
            }
          }
        },
        scales: {
          x: { min: -30, max: 60, title: { display: true, text: 'Excess Events per 10,000 Person-Years' } },
          y: { grid: { display: false } }
        }
      }
    });

    // Chart 4: Benefits
    new Chart(document.getElementById('chart-benefits'), {
      type: 'bar',
      data: {
        labels: ['Vasomotor Symptoms', 'CVD (early initiation)', 'Hip Fracture', 'Dementia (early)', 'All Fractures', 'Breast Cancer (ET)', 'Diabetes'],
        datasets: [{
          label: 'Risk Reduction (%)',
          data: [64, 50, 34, 32, 24, 23, 17],
          backgroundColor: 'rgba(34, 197, 94, 0.8)',
          borderColor: 'rgba(34, 197, 94, 1)',
          borderWidth: 2,
          borderRadius: 6
        }]
      },
      options: {
        indexAxis: 'y',
        responsive: true,
        maintainAspectRatio: false,
        plugins: {
          legend: { display: false },
          tooltip: { callbacks: { label: (ctx) => `${ctx.raw}% risk reduction` } }
        },
        scales: {
          x: { beginAtZero: true, max: 70, title: { display: true, text: 'Risk Reduction (%)' } },
          y: { grid: { display: false } }
        }
      }
    });

    // Chart 5: Breast Cancer
    new Chart(document.getElementById('chart-breast'), {
      type: 'bar',
      data: {
        labels: ['No HRT (Baseline)', 'Estrogen-Only', 'Combined + Natural Prog.', 'Combined + Synthetic'],
        datasets: [{
          label: 'Relative Risk',
          data: [1.0, 0.77, 1.08, 1.24],
          backgroundColor: ['rgba(148, 163, 184, 0.8)', 'rgba(34, 197, 94, 0.8)', 'rgba(251, 191, 36, 0.8)', 'rgba(239, 68, 68, 0.8)'],
          borderColor: ['rgba(148, 163, 184, 1)', 'rgba(34, 197, 94, 1)', 'rgba(251, 191, 36, 1)', 'rgba(239, 68, 68, 1)'],
          borderWidth: 2,
          borderRadius: 8
        }]
      },
      options: {
        responsive: true,
        maintainAspectRatio: false,
        plugins: {
          legend: { display: false },
          annotation: {
            annotations: { line1: { type: 'line', yMin: 1, yMax: 1, borderColor: 'rgba(100, 116, 139, 0.7)', borderWidth: 2, borderDash: [6, 4] } }
          }
        },
        scales: {
          y: { beginAtZero: true, max: 1.4, title: { display: true, text: 'Relative Risk' } },
          x: { grid: { display: false } }
        }
      }
    });

    // Chart 6: VTE Route
    new Chart(document.getElementById('chart-vte'), {
      type: 'bar',
      data: {
        labels: ['Oral HRT', 'Transdermal HRT'],
        datasets: [{
          label: 'Relative Risk of VTE',
          data: [1.9, 1.0],
          backgroundColor: ['rgba(239, 68, 68, 0.8)', 'rgba(34, 197, 94, 0.8)'],
          borderColor: ['rgba(239, 68, 68, 1)', 'rgba(34, 197, 94, 1)'],
          borderWidth: 3,
          borderRadius: 10,
          barThickness: 80
        }]
      },
      options: {
        responsive: true,
        maintainAspectRatio: false,
        plugins: {
          legend: { display: false },
          tooltip: {
            callbacks: {
              label: (ctx) => {
                const rr = ctx.raw;
                if (rr > 1) return `${Math.round((rr-1)*100)}% increased VTE risk`;
                return 'No increased VTE risk';
              }
            }
          },
          annotation: {
            annotations: { line1: { type: 'line', yMin: 1, yMax: 1, borderColor: 'rgba(100, 116, 139, 0.7)', borderWidth: 2, borderDash: [6, 4] } }
          }
        },
        scales: {
          y: { beginAtZero: true, max: 2.2, title: { display: true, text: 'Relative Risk' } },
          x: { grid: { display: false } }
        }
      }
    });
  </script>
</body>
</html>
